Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study)

Journal of Allergy and Clinical Immunology

Volumn 109, Issue 2, 2002, Pages 251-256

  M̈ller, Christian ^a   Dreborg, Sten ^a   Ferdousi, Hosne A ^a   Halken, Susanne ^a   Høst, Arne ^a   Jacobsen, Lars ^a   Koivikko, Antti ^a   Koller, Dieter Y ^a   Niggemann, Bodo ^a   Norberg, Lene A ^a   Urbanek, Radvan ^a   Valovirta, Erkka ^a   Wahn, Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Asthma; Bronchial hyperresponsiveness; Prevention; Rhinitis; Specific immunotherapy

Indexed keywords

BUDESONIDE; CROMOGLYCATE DISODIUM; LEVOCABASTINE; LORATADINE; METHACHOLINE;

ADOLESCENT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CHILD; FEMALE; GRASS POLLEN; HAY FEVER; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROVOCATION TEST; RHINOCONJUNCTIVITIS; WINTER;

EID: 0036170801     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.121317     Document Type: Article

References (34)

1. Mechanisms of nose-lung interaction
2. Allergic rhinobronchitis: The asthma-allergic rhinitis link
3. Asthma and allergic rhinitis in the same patients
4. Asthma in children. A follow-up study of 688 patients after an interval of twenty years
5. A 10-year prognosis for childhood allergic rhinitis
6. Bronchial sensitivity to methacholine in current and former asthmatic and allergic rhinitis patients and control subjects
7. Asymptomatic bronchial hyperresponsiveness in rhinitis
8. Comparative action of acetylbeta-methylcholine, histamine, and pollen antigens in subjects with hay fever and patients with bronchial asthma
9. Asthma, bronchial hyperreactivity and mediator release in children with birch pollinosis. ECP and EPX levels are not related to bronchial hyperreactivity
10. Seasonal increase of bronchial reactivity in allergic rhinitis
11. Asthma and allergic rhinitis in the same patients
12. Long-term risk factors for developing asthma and allergic rhinitis: A 23-year follow-up study of college students
13. Airway hyperresponsiveness in allergic rhinitis. A risk factor for asthma
14. Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a 3-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel
15. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients
16. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs
17. Grass pollen immunotherapy: Efficacy and safety during a 4-year follow-up study
18. A double-blind, randomized study investigating the efficacy and specificity of immunotherapy with Artemisia vulgaris or Phleum pratense/betula verrucosa
19. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up
20. Pediatric pecularities of immunotherapy
21. The value of hyposensitization therapy for bronchial asthma in children - A 14-year study
22. Long-term clinical efficacy of grass-pollen immunotherapy
23. Skin prick test. Position paper of the European Academy of Allergology and Clinical Immunology
24. The precision of the conjunctival provocation test
25. A new aerosol device for bronchial provocation tests
26. Longitudinal data analysis using generalized linear models
27. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group
28. Prevalence of bronchial reactivity to inhaled methacholine in New Zealand children
29. Nonspecific bronchial reactivity and its relationship to the clinical expression of asthma. A longitudinal study
30. Seasonal variation of airway function in allergic rhinitis
31. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy
32. Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen
33. Immunotherapy with a standardized Dermatophagoldes pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children